FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007137213> ?p ?o ?g. }

• W2007137213 endingPage "746" @default.
• W2007137213 startingPage "738" @default.
• W2007137213 abstract "Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation.BackgroundEpidemiological data implicate that renal transplants from living unrelated donors result in superior survival rates as compared with cadaveric grafts, despite a higher degree of human lymphocyte antigen (HLA) mismatching. We undertook a center-based case control study to identify donor-specific determinants affecting early outcome in cadaveric transplantation.MethodsThe study database consisted of 152 consecutive cadaveric renal transplants performed at our center between June 1989 and September 1998. Of these, 24 patients received a retransplant. Donor kidneys were allocated on the basis of prospective HLA matching according to the Eurotransplant rules of organ sharing. Immunosuppressive therapy consisted of a cyclosporine-based triple-drug regimen. In 67 recipients, at least one acute rejection episode occurred during the first month after transplantation. They were taken as cases, and the remaining 85 patients were the controls. Stepwise logistic regression was done on donor-specific explanatory variables obtained from standardized Eurotransplant Necrokidney reports. In a secondary evaluation, the impact on graft survival in long-term follow-up was further measured by applying a Cox regression model. The mean follow-up of all transplant recipients was 3.8 years (sd 2.7 years).ResultsDonor age [odds ratio (OR) 1.05; 95% CI, 1.02 to 1.08], traumatic brain injury as cause of death (OR 2.75; 95% CI, 1.16 to 6.52), and mismatch on HLA-DR (OR 3.0; 95% CI, 1.47 to 6.12) were associated with an increased risk of acute rejection, whereas donor use of dopamine (OR 0.22; 95% CI, 0.09 to 0.51) and/or noradrenaline (OR 0.24; 95% CI, 0.10 to 0.60) independently resulted in a significant beneficial effect. In the multivariate Cox regression analysis, both donor treatment with dopamine (HR 0.44; 95% CI, 0.22 to 0.84) and noradrenaline (HR 0.30; 95% CI, 0.10 to 0.87) remained a significant predictor of superior graft survival in long-term follow-up.ConclusionsOur data strongly suggest that the use of catecholamines in postmortal organ donors during intensive care results in immunomodulating effects and improves graft survival in long-term follow-up. These findings may at least partially be explained by down-regulating effects of adrenergic substances on the expression of adhesion molecules (VCAM, E-selectin) in the vessel walls of the graft. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Epidemiological data implicate that renal transplants from living unrelated donors result in superior survival rates as compared with cadaveric grafts, despite a higher degree of human lymphocyte antigen (HLA) mismatching. We undertook a center-based case control study to identify donor-specific determinants affecting early outcome in cadaveric transplantation. The study database consisted of 152 consecutive cadaveric renal transplants performed at our center between June 1989 and September 1998. Of these, 24 patients received a retransplant. Donor kidneys were allocated on the basis of prospective HLA matching according to the Eurotransplant rules of organ sharing. Immunosuppressive therapy consisted of a cyclosporine-based triple-drug regimen. In 67 recipients, at least one acute rejection episode occurred during the first month after transplantation. They were taken as cases, and the remaining 85 patients were the controls. Stepwise logistic regression was done on donor-specific explanatory variables obtained from standardized Eurotransplant Necrokidney reports. In a secondary evaluation, the impact on graft survival in long-term follow-up was further measured by applying a Cox regression model. The mean follow-up of all transplant recipients was 3.8 years (sd 2.7 years). Donor age [odds ratio (OR) 1.05; 95% CI, 1.02 to 1.08], traumatic brain injury as cause of death (OR 2.75; 95% CI, 1.16 to 6.52), and mismatch on HLA-DR (OR 3.0; 95% CI, 1.47 to 6.12) were associated with an increased risk of acute rejection, whereas donor use of dopamine (OR 0.22; 95% CI, 0.09 to 0.51) and/or noradrenaline (OR 0.24; 95% CI, 0.10 to 0.60) independently resulted in a significant beneficial effect. In the multivariate Cox regression analysis, both donor treatment with dopamine (HR 0.44; 95% CI, 0.22 to 0.84) and noradrenaline (HR 0.30; 95% CI, 0.10 to 0.87) remained a significant predictor of superior graft survival in long-term follow-up. Our data strongly suggest that the use of catecholamines in postmortal organ donors during intensive care results in immunomodulating effects and improves graft survival in long-term follow-up. These findings may at least partially be explained by down-regulating effects of adrenergic substances on the expression of adhesion molecules (VCAM, E-selectin) in the vessel walls of the graft." @default.
• W2007137213 created "2016-06-24" @default.
• W2007137213 creator A5006585425 @default.
• W2007137213 creator A5060121492 @default.
• W2007137213 creator A5063907951 @default.
• W2007137213 creator A5084738023 @default.
• W2007137213 creator A5087694319 @default.
• W2007137213 date "1999-08-01" @default.
• W2007137213 modified "2023-10-14" @default.
• W2007137213 title "Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation" @default.
• W2007137213 cites W1548820511 @default.
• W2007137213 cites W1578438134 @default.
• W2007137213 cites W1578996543 @default.
• W2007137213 cites W1690233168 @default.
• W2007137213 cites W1904022644 @default.
• W2007137213 cites W1969667211 @default.
• W2007137213 cites W1980276519 @default.
• W2007137213 cites W1984427644 @default.
• W2007137213 cites W1984466510 @default.
• W2007137213 cites W1990038658 @default.
• W2007137213 cites W2005418051 @default.
• W2007137213 cites W2009355559 @default.
• W2007137213 cites W2027809685 @default.
• W2007137213 cites W2043559468 @default.
• W2007137213 cites W2050124878 @default.
• W2007137213 cites W2052307789 @default.
• W2007137213 cites W2060019350 @default.
• W2007137213 cites W2060508116 @default.
• W2007137213 cites W2060728914 @default.
• W2007137213 cites W2061360674 @default.
• W2007137213 cites W2062692680 @default.
• W2007137213 cites W2069470048 @default.
• W2007137213 cites W2090521704 @default.
• W2007137213 cites W2124868627 @default.
• W2007137213 cites W2315888271 @default.
• W2007137213 cites W2342967759 @default.
• W2007137213 cites W2413778605 @default.
• W2007137213 cites W4230693812 @default.
• W2007137213 cites W85338961 @default.
• W2007137213 doi "https://doi.org/10.1046/j.1523-1755.1999.00567.x" @default.
• W2007137213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10432416" @default.
• W2007137213 hasPublicationYear "1999" @default.
• W2007137213 type Work @default.
• W2007137213 sameAs 2007137213 @default.
• W2007137213 citedByCount "117" @default.
• W2007137213 countsByYear W20071372132012 @default.
• W2007137213 countsByYear W20071372132013 @default.
• W2007137213 countsByYear W20071372132014 @default.
• W2007137213 countsByYear W20071372132015 @default.
• W2007137213 countsByYear W20071372132016 @default.
• W2007137213 countsByYear W20071372132017 @default.
• W2007137213 countsByYear W20071372132018 @default.
• W2007137213 countsByYear W20071372132019 @default.
• W2007137213 countsByYear W20071372132020 @default.
• W2007137213 countsByYear W20071372132021 @default.
• W2007137213 countsByYear W20071372132022 @default.
• W2007137213 crossrefType "journal-article" @default.
• W2007137213 hasAuthorship W2007137213A5006585425 @default.
• W2007137213 hasAuthorship W2007137213A5060121492 @default.
• W2007137213 hasAuthorship W2007137213A5063907951 @default.
• W2007137213 hasAuthorship W2007137213A5084738023 @default.
• W2007137213 hasAuthorship W2007137213A5087694319 @default.
• W2007137213 hasBestOaLocation W20071372131 @default.
• W2007137213 hasConcept C126322002 @default.
• W2007137213 hasConcept C141071460 @default.
• W2007137213 hasConcept C156957248 @default.
• W2007137213 hasConcept C175696284 @default.
• W2007137213 hasConcept C2780091579 @default.
• W2007137213 hasConcept C2780252810 @default.
• W2007137213 hasConcept C2780303639 @default.
• W2007137213 hasConcept C2911091166 @default.
• W2007137213 hasConcept C50382708 @default.
• W2007137213 hasConcept C71924100 @default.
• W2007137213 hasConceptScore W2007137213C126322002 @default.
• W2007137213 hasConceptScore W2007137213C141071460 @default.
• W2007137213 hasConceptScore W2007137213C156957248 @default.
• W2007137213 hasConceptScore W2007137213C175696284 @default.
• W2007137213 hasConceptScore W2007137213C2780091579 @default.
• W2007137213 hasConceptScore W2007137213C2780252810 @default.
• W2007137213 hasConceptScore W2007137213C2780303639 @default.
• W2007137213 hasConceptScore W2007137213C2911091166 @default.
• W2007137213 hasConceptScore W2007137213C50382708 @default.
• W2007137213 hasConceptScore W2007137213C71924100 @default.
• W2007137213 hasIssue "2" @default.
• W2007137213 hasLocation W20071372131 @default.
• W2007137213 hasLocation W20071372132 @default.
• W2007137213 hasOpenAccess W2007137213 @default.
• W2007137213 hasPrimaryLocation W20071372131 @default.
• W2007137213 hasRelatedWork W1978190320 @default.
• W2007137213 hasRelatedWork W2090748462 @default.
• W2007137213 hasRelatedWork W2159883148 @default.
• W2007137213 hasRelatedWork W2404993709 @default.
• W2007137213 hasRelatedWork W2407111357 @default.
• W2007137213 hasRelatedWork W2461145225 @default.
• W2007137213 hasRelatedWork W4242300793 @default.
• W2007137213 hasRelatedWork W98571183 @default.
• W2007137213 hasRelatedWork W2420893955 @default.
• W2007137213 hasRelatedWork W2516580965 @default.

• next